Skip to main content
. 2019 Mar 26;85(5):704–714. doi: 10.1002/ana.25450

Table 2.

Subjects Experiencing Treatment Emergent Serious Adverse Events and Adverse Events Occuring in >1 Subject In Any Cohort by MedRA System Organ Class

Cohort 1 7·5 × 1011vg (N = 5) Cohort 2 1·5 × 1012vg (N = 5) Cohort 3 4·7 × 1012vg (N = 5) Total (N = 15)
Any adverse event 5 5 5 15
Any serious averse event 0 1a 0 1
Gastrointestinal disorders
Constipation 1 2 0 3
Vomiting 1 1 0 2
Infections and infestations
Tooth abcess 2 0 0 2
Upper respiratory tract infection 2 0 1 3
Metabolism and nutrition disorders
Vitamin B12 deficiency 0 2 0 2
Musculoskeletal and connective tissue disorders
Back pain 2 2 0 4
Musculoskeletal pain 3 0 1 4
Nervous system disorders
Dizziness 2 0 0 2
Dyskinesia 2 1 1 4
Headache 5 3 3 11
Hypoaesthesia 3 1 3 7
Memory impairment 2 0 0 2
Neuralgia 2 0 0 2
Psychiatric disorders
Depression 2 1 0 3
Vascular disorders
Orthostatic hypotension 2 0 0 2
a

One participant experienced a deep venous thrombosis, pulmonary embolus, and subsequent atrial fibrillation, likely attributed to immobility during the surgery.

MedRA = Medical Dictionary for Regulatory Activities; vg = vector genomes.